255 related articles for article (PubMed ID: 32467177)
1. Industry One-Voice-of-Quality (1VQ) Solutions: Effective Management of Post-Approval Changes in the Pharmaceutical Quality System (PQS)-through Enhanced Science and Risk-Based Approaches.
Ramnarine E; Vinther A; Bruhin K; Tovar C; Colao M
PDA J Pharm Sci Technol; 2020; 74(4):456-467. PubMed ID: 32467177
[TBL] [Abstract][Full Text] [Related]
2. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
Vinther A; Ramnarine E
PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
[TBL] [Abstract][Full Text] [Related]
3. Industry One-Voice-of-Quality Solutions Management Review of Post-Approval Changes Guide.
Vinther A; Mohammed F; Ramnarine E
PDA J Pharm Sci Technol; 2021; 75(5):454-457. PubMed ID: 33723006
[TBL] [Abstract][Full Text] [Related]
4. Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability.
Vinther A; Ramnarine E; Gastineau T; O'Brien L; Brehm O; Fryrear D
Ther Innov Regul Sci; 2024 May; 58(3):433-442. PubMed ID: 38369639
[TBL] [Abstract][Full Text] [Related]
5. ICH Q10 Pharmaceutical Quality System Guidance: Understanding Its Impact on Pharmaceutical Quality.
VanDuyse SA; Fulford MJ; Bartlett MG
AAPS J; 2021 Nov; 23(6):117. PubMed ID: 34773177
[TBL] [Abstract][Full Text] [Related]
6. Managing Excipient Supplier Name and Address Changes in the Pharmaceutical Quality System.
Rolke R; Ramnarine E; Vinther A; Sawant A
PDA J Pharm Sci Technol; 2020; 74(2):286-288. PubMed ID: 32179712
[TBL] [Abstract][Full Text] [Related]
7. Knowledge Management as a Pharmaceutical Quality System Enabler: How Enhanced Knowledge Transfer Can Help Close the ICH Q10 to ICH Q12 Gap.
Lipa MJ; Greene A; Calnan N
PDA J Pharm Sci Technol; 2021; 75(1):64-90. PubMed ID: 32675306
[TBL] [Abstract][Full Text] [Related]
8. Enabling ICH Q10 Implementation--Part 1. Striving for Excellence by Embracing ICH Q8 and ICH Q9.
Calnan N; O'Donnell K; Greene A
PDA J Pharm Sci Technol; 2013; 67(6):581-600. PubMed ID: 24265300
[TBL] [Abstract][Full Text] [Related]
9. A practical discussion of risk management for manufacturing of pharmaceutical products.
Mollah AH; Baseman HS; Long M; Rathore AS
PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
[TBL] [Abstract][Full Text] [Related]
10.
Ramnarine E; O'Donnell K
PDA J Pharm Sci Technol; 2018; 72(3):338-345. PubMed ID: 29669814
[TBL] [Abstract][Full Text] [Related]
11. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
[TBL] [Abstract][Full Text] [Related]
12. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
Steinwandter V; Herwig C
PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
[TBL] [Abstract][Full Text] [Related]
13. Risk-Based Approach for Analytical Comparability and Comparability Protocols.
Iyer KR; Lequeux I
PDA J Pharm Sci Technol; 2020; 74(5):563-570. PubMed ID: 32295861
[TBL] [Abstract][Full Text] [Related]
14. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality.
O'Connor TF; Yu LX; Lee SL
Int J Pharm; 2016 Jul; 509(1-2):492-498. PubMed ID: 27260134
[TBL] [Abstract][Full Text] [Related]
15. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
16. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
17. [Pharmaceutical product quality control and good manufacturing practices].
Hiyama Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
[TBL] [Abstract][Full Text] [Related]
18. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
[TBL] [Abstract][Full Text] [Related]
19. Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm.
Van Buskirk GA; Asotra S; Balducci C; Basu P; DiDonato G; Dorantes A; Eickhoff WM; Ghosh T; González MA; Henry T; Howard M; Kamm J; Laurenz S; MacKenzie R; Mannion R; Noonan PK; Ocheltree T; Pai U; Poska RP; Putnam ML; Raghavan RR; Ruegger C; Sánchez E; Shah VP; Shao ZJ; Somma R; Tammara V; Thombre AG; Thompson B; Timko RJ; Upadrashta S; Vaithiyalingam S;
AAPS PharmSciTech; 2014 Jun; 15(3):665-93. PubMed ID: 24578237
[TBL] [Abstract][Full Text] [Related]
20. Understanding Quality Paradigm Shifts in the Evolving Pharmaceutical Landscape: Perspectives from the USP Quality Advisory Group.
Weitzel J; Pappa H; Banik GM; Barker AR; Bladen E; Chirmule N; DeFeo J; Devine J; Emrick S; Hout TK; Levy MS; Mahlangu GN; Rellahan B; Venema J; Workman W
AAPS J; 2021 Oct; 23(6):112. PubMed ID: 34654974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
